1-3 of 3
Kurt Krejcy, PhD
Close
Sort by
Journal Articles

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Heinz Gisslinger, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, MD PhD, Viktor Rossiev, Petr Dulicek, Arpad Illes, MD, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, Kurt Krejcy, PhD, Barbara Grohmann-Izay, MD MSc, Hans Carl Hasselbalch, Professor, dr.MD, Robert Kralovics, PhD, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 579.
https://doi.org/10.1182/blood-2018-99-118715
Published: 2018
Journal Articles

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, MSc, Kurt Krejcy, PhD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, PhD, Maria-Theresa Krauth, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3029.
https://doi.org/10.1182/blood-2018-99-119268
Published: 2018
Journal Articles

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

Heinz Gisslinger, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, Liana Gercheva, MD PhD, Miklos Egyed, MD PhD, Viktor Rossiev, Petr Dulicek, Árpád Illés, MD PhD, Halyna Pylypenko, MD, Lylia Sicheva, Jiri Mayer, Prof, MD SCs, Vera Yablokova, Kurt Krejcy, PhD, Barbara Grohmann-Izay, MD MSc, Hans Carl Hasselbalch, MD Professor, DMSc, Robert Kralovics, PhD, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 320.
https://doi.org/10.1182/blood.V130.Suppl_1.320.320
Published: 2017